Literature DB >> 25022535

Do NIA-AA criteria distinguish Alzheimer's disease from frontotemporal dementia?

Jennifer M Harris1, Jennifer C Thompson2, Claire Gall2, Anna M T Richardson1, David Neary1, Daniel du Plessis2, Piyali Pal2, David M A Mann1, Julie S Snowden1, Matthew Jones3.   

Abstract

BACKGROUND: Clinical criteria are important for improving diagnostic accuracy and ensuring comparability of patient cohorts in research studies.
OBJECTIVE: The aim was to assess the National Institute on Aging and Alzheimer's Association (NIA-AA) criteria for Alzheimer's disease (AD) dementia in AD and frontotemporal lobar degeneration (FTLD).
METHODS: Two hundred twelve consecutive patients with pathologically confirmed AD or FTLD who were clinically assessed in a specialist cognitive unit were identified. Fifty-five patients were excluded predominantly because of insufficient clinical information. Anonymized clinical data were rated against the NIA-AA criteria by raters who were blinded to clinical and pathologic diagnosis.
RESULTS: The NIA-AA AD dementia criteria had a sensitivity of 65.6% for probable and 79.5% for possible AD and a specificity of 95.2% and 94.0% for probable and possible, respectively.
CONCLUSION: In patients with FTLD and predominantly early-onset AD, the NIA-AA AD dementia criteria have high specificity but lower sensitivity. The high specificity is due to the broad exclusion criteria.
Copyright © 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease; Criteria; Dementia; Diagnosis; Neuropathology; Pathology

Mesh:

Year:  2014        PMID: 25022535     DOI: 10.1016/j.jalz.2014.04.516

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  10 in total

1.  ATN incorporating cerebrospinal fluid neurofilament light chain detects frontotemporal lobar degeneration.

Authors:  Katheryn A Q Cousins; Jeffrey S Phillips; David J Irwin; Edward B Lee; David A Wolk; Leslie M Shaw; Henrik Zetterberg; Kaj Blennow; Sarah E Burke; Nikolas G Kinney; Garrett S Gibbons; Corey T McMillan; John Q Trojanowski; Murray Grossman
Journal:  Alzheimers Dement       Date:  2020-11-23       Impact factor: 21.566

2.  Multiparametric computer-aided differential diagnosis of Alzheimer's disease and frontotemporal dementia using structural and advanced MRI.

Authors:  Esther E Bron; Marion Smits; Janne M Papma; Rebecca M E Steketee; Rozanna Meijboom; Marius de Groot; John C van Swieten; Wiro J Niessen; Stefan Klein
Journal:  Eur Radiol       Date:  2016-12-16       Impact factor: 5.315

3.  Automatic normative quantification of brain tissue volume to support the diagnosis of dementia: A clinical evaluation of diagnostic accuracy.

Authors:  Meike W Vernooij; Bas Jasperse; Rebecca Steketee; Marcel Koek; Henri Vrooman; M Arfan Ikram; Janne Papma; Aad van der Lugt; Marion Smits; Wiro J Niessen
Journal:  Neuroimage Clin       Date:  2018-08-09       Impact factor: 4.881

4.  Neuropsychological differentiation of progressive aphasic disorders.

Authors:  Jennifer M Harris; Jennifer A Saxon; Matthew Jones; Julie S Snowden; Jennifer C Thompson
Journal:  J Neuropsychol       Date:  2018-02-08       Impact factor: 2.864

5.  Amyloid-β PET-Correlation with cerebrospinal fluid biomarkers and prediction of Alzheimer´s disease diagnosis in a memory clinic.

Authors:  Ebba Gløersen Müller; Trine Holt Edwin; Caroline Stokke; Sigrid Stensby Navelsaker; Almira Babovic; Nenad Bogdanovic; Anne Brita Knapskog; Mona Elisabeth Revheim
Journal:  PLoS One       Date:  2019-08-20       Impact factor: 3.240

6.  Safety and tolerability of GRF6019 in mild-to-moderate Alzheimer's disease dementia.

Authors:  Jonas Hannestad; Katie Koborsi; Vicki Klutzaritz; Whitney Chao; Rebecca Ray; Antonio Páez; Sam Jackson; Scott Lohr; Jeffrey L Cummings; Gary Kay; Karoly Nikolich; Steven Braithwaite
Journal:  Alzheimers Dement (N Y)       Date:  2020-12-16

7.  A Pragmatic, Data-Driven Method to Determine Cutoffs for CSF Biomarkers of Alzheimer Disease Based on Validation Against PET Imaging.

Authors:  Julien Dumurgier; Séverine Sabia; Henrik Zetterberg; Charlotte E Teunissen; Bernard Hanseeuw; Adelina Orellana; Susanna Schraen; Audrey Gabelle; Mercè Boada; Thibaud Lebouvier; Eline A J Willemse; Emmanuel Cognat; Agustin Ruiz; Claire Hourregue; Matthieu Lilamand; Elodie Bouaziz-Amar; Jean-Louis Laplanche; Sylvain Lehmann; Florence Pasquier; Philip Scheltens; Kaj Blennow; Archana Singh-Manoux; Claire Paquet
Journal:  Neurology       Date:  2022-05-26       Impact factor: 11.800

8.  Joint assessment of white matter integrity, cortical and subcortical atrophy to distinguish AD from behavioral variant FTD: A two-center study.

Authors:  Christiane Möller; Anne Hafkemeijer; Yolande A L Pijnenburg; Serge A R B Rombouts; Jeroen van der Grond; Elise Dopper; John van Swieten; Adriaan Versteeg; Petra J W Pouwels; Frederik Barkhof; Philip Scheltens; Hugo Vrenken; Wiesje M van der Flier
Journal:  Neuroimage Clin       Date:  2015-09-09       Impact factor: 4.881

9.  Apraxia profiles-A single cognitive marker to discriminate all variants of frontotemporal lobar degeneration and Alzheimer's disease.

Authors:  Andreas Johnen; Sophia Reul; Heinz Wiendl; Sven G Meuth; Thomas Duning
Journal:  Alzheimers Dement (Amst)       Date:  2018-05-16

10.  Validity of the 2014 traumatic encephalopathy syndrome criteria for CTE pathology.

Authors:  Jesse Mez; Michael L Alosco; Daniel H Daneshvar; Nicole Saltiel; Zachary Baucom; Bobak Abdolmohammadi; Madeline Uretsky; Raymond Nicks; Brett M Martin; Joseph N Palmisano; Christopher J Nowinski; Philip Montenigro; Todd M Solomon; Ian Mahar; Jonathan D Cherry; Victor E Alvarez; Brigid Dwyer; Lee E Goldstein; Douglas I Katz; Robert C Cantu; Neil W Kowall; Yorghos Tripodis; Bertrand R Huber; Thor D Stein; Robert A Stern; Ann C McKee
Journal:  Alzheimers Dement       Date:  2021-04-07       Impact factor: 21.566

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.